XML 62 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Non-options (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2022
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Weighted average price          
Share-based compensation costs recognized     $ 4,877 $ 3,825  
BTI RSU          
Number of shares          
Outstanding, beginning balance (in shares)     119,000    
Granted (in shares) 25,000   131,000   122,000
Vested (in shares)     (25,000)    
Outstanding, ending balance (in shares)     225,000   119,000
Weighted average price          
Weighted average grant date fair value (in dollars per share) $ 10.76 $ 15.31 $ 19.60    
Vesting period     4 years   4 years
Vesting (as a percent)     25.00%   25.00%
BTI RSU | Employee          
Weighted average price          
Vesting period 1 year        
Vesting (as a percent) 100.00%        
BTI RSU | Nonemployee consultant          
Weighted average price          
Vesting (as a percent) 50.00%        
BTI RSU | Grant Date 2023          
Weighted average price          
Unrecognized stock-based compensation expense     $ 2,539    
BTI RSU | Grant Date 2022          
Weighted average price          
Unrecognized stock-based compensation expense     $ 1,067    
OnkosXcel PSUs          
Number of shares          
Outstanding, beginning balance (in shares)     1,310    
Granted (in shares)     15    
Outstanding, ending balance (in shares)     1,325   1,310
Vested aggregate (in shares)     333    
Weighted average price          
Weighted average price (in dollars per share)         $ 5,506
Weighted average grant date fair value (in dollars per share)     $ 10,176    
Weighted average price, aggregate vested (in dollars per share)     $ 5,506    
Vesting period     48 months    
Unrecognized stock-based compensation expense     $ 4,219    
Weighted average fair value of non-options granted (in dollars per share)     $ 8    
OnkosXcel PSUs | Executive officers          
Weighted average price          
Vesting period     24 months    
OnkosXcel RSUs          
Number of shares          
Granted (in shares)     225    
Outstanding, ending balance (in shares)     225    
Weighted average price          
Weighted average grant date fair value (in dollars per share)     $ 10    
Unrecognized stock-based compensation expense     $ 2,194    
OnkosXcel RSUs | Tranche One          
Number of shares          
Granted (in shares)     125,000    
Weighted average price          
Vesting period after IPO     180 days    
OnkosXcel RSUs | Tranche Two          
Weighted average price          
Vesting period     4 years    
Vesting (as a percent)     25.00%